Benefits of fixed-dose combination therapy with inhaled corticosteroids and long-acting bronchodilators as initial maintenance therapy in the management of asthma

Respirology

Volumn 14, Issue 2, 2009, Pages 224-229

  Seale, J Paul ^a,b   Jenkins, Christine ^b,c   Wood Baker, Richard ^d   Neville, A Munro ^e  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ANZAC Research Institute   (Australia)

^d Pretium Pty Ltd   (Australia)

^e UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Asthma; Fixed dose combination therapy; Inhaled corticosteroids; Initial treatment; Steroid na ve

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE;

ARTICLE; ASTHMA; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME;

EID: 61349113375     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2008.01440.x     Document Type: Article

References (20)

1. Australian Centre for Asthma Monitoring. Asthma in Australia: findings from the 2004-2005 National Health Survey. Cat. No. ACM 10: Australian Institute of Health and Welfare, Canberra (ACT 2007.
2. Australian Bureau of Statistics. 2001 National Health Survey: Summary of Results. ABS Cat. No. 4364.0: Australian Bureau of Statistics, Canberra (ACT 2002.
3. Marks GB, Abramson MJ, Jenkins CR, Kenny P, Mellis CM et al. Asthma management and outcomes in Australia: a nation-wide telephone interview survey. Respirology 2007 12 : 212 19.
4. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am. J. Respir. Crit. Care Med. 2004 170 : 836 44.
5. O'Byrne P, Barnes PJ, Rodriguez-Gomez G, Runnerstrom E, Sandstrom T et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am. J. Respir. Crit. Care Med. 2001 164 : 1392 7.
6. National Asthma Council Australia. Asthma Management Handbook 2006. National Asthma Council Australia Ltd, Melbourne, Vic., Australia, 2006.
7. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996 153 : 1481 8.
8. Greening AP, Ind PW, Northfield M. Shaw G, on behalf of Allen & Hanburys Limited UK Study Group. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994 344 : 219 24.
9. Walters JAE, Wood-Baker R, Walters EH. Long-acting beta2-agonists in asthma: an overview of Cochrane systematic reviews. Respir. Med. 2005 99 : 384 95.
10. Pearlman DS, Stricker W, Weinstein S, Gross G, Chervinsky P et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann. Allergy Asthma Immunol. 1999 82 : 257 65.
11. Lange ML, House KW, Scott A, Shah TP, Akveld MLM. The salmeterol/fluticasone propionate combination 50/100 μg bid is effective as initial maintenance therapy in mild and moderate asthmatics. Eur. Respir. J. 2001 18 : 176s.
12. Nelson HS, Wolfe JD, Gross D, Geos LS, Bailinger L et al. Efficacy and safety of fluticasone propionate 44 mcg/salmeterol 21 mcg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Ann. Allergy Asthma Immunol. 2003 91 : 263 9.
13. Murray J, Rosenthal R, Somerville L, Blake K, House K et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta-2 agonists. Ann. Allergy Asthma Immunol. 2004 93 : 351 9.
14. Boonsawat W, Goryachkina L, Millns H, Balsara S. The efficacy and safety of Seretide/Advair TM once daily (50/100 mcg) compared with fluticasone propionate (100 mcg) once daily and the placebo as initial maintenance therapy in mild asthma. Am. J. Respir. Crit. Care Med. 2004 169 : A86.
15. McCarthy TP, Russell D, Baxter LE, Shrewsbury SB, Rice L. A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclomethasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone. Eur. Respir. J. 2001 18 : 53s.
16. Strand AM, Lucknow A. Danish initiative for asthma treatment. Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Respir. Med. 2004 98 : 1008 15.
17. GSK Clinical Trials Register. FNM30021 (FLIT 11) [Online Accessed 14 November 2004.] Available from URL: http://ctr.gsk.co.uk/Summary/fluticasone- propionate/studylist.asp.
18. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV et al. Daily versus as-needed corticosteroids for mild persistent asthma. N. Engl. J. Med. 2005 352 : 1519 28.
19. Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N. Engl. J. Med. 2007 356 : 2040 52.
20. American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N. Engl. J. Med. 2007 356 : 2027 39.